TaiRx, Inc. (TPEX:6580)
24.60
-0.50 (-1.99%)
Sep 5, 2025, 1:50 PM CST
TaiRx Revenue
TaiRx had revenue of 7.96M TWD in the half year ending December 31, 2024, with 26.20% growth. This brings the company's revenue in the last twelve months to 15.46M, up 190.62% year-over-year. In the year 2024, TaiRx had annual revenue of 8.22M with 61.79% growth.
Revenue (ttm)
15.46M
Revenue Growth
+190.62%
P/S Ratio
176.12
Revenue / Employee
n/a
Employees
29
Market Cap
2.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.22M | 3.14M | 61.79% |
Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
Dec 31, 2020 | 3.36M | 203.00K | 6.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Lumosa Therapeutics | 37.25M |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Center Laboratories | 1.60B |